Drug Warning Labels: FDA Seeks Feedback Loop
Published Date: 1/27/2026
Notice
Summary
The FDA wants your thoughts on how they collect info about Medication Guides that come with prescription drugs. This affects drug makers and patients who rely on these guides to use medicines safely. You’ve got until March 30, 2026, to share your comments, helping shape how these important guides are handled without adding extra costs or paperwork.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
Drugmakers’ Large Time Burden
Holders and sponsors of drug applications will prepare and submit Medication Guides: FDA estimates 70 application holders will each submit one Medication Guide annually and spend about 320 hours each (total ~22,400 hours). FDA also estimates one sponsor will request an exemption annually (4 hours), for a combined total of 71 responses and 22,404 hours annually.
Distributors’ Distribution Workload
FDA estimates 191 distributors will provide Medication Guides to about 9,000 authorized dispensers annually, resulting in 1,719,000 disclosures and an average burden of 1.25 hours per disclosure (total ~2,148,750 hours per year).
Pharmacies’ Time to Give Guides to Patients
FDA estimates 88,736 authorized dispensers (pharmacies/pharmacists) will make about 506,238,880 disclosures annually, spending about 3 minutes (0.05 hours) per disclosure for a total of ~25,311,944 hours per year to provide Medication Guides to patients as required by 21 CFR 208.24(e).
Patients Receive Required Medication Guides
Medication Guides are required to be provided directly to the patient (or the patient's agent) upon dispensing for applicable prescription drugs; FDA says these guides give important information about approved uses, contraindications, adverse reactions, and cautions and are intended to help patients use certain medications most safely and effectively.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2026-01575, Determination of Regulatory Review Period for Purposes of Patent Extension; IMAAVY
The FDA has officially set the review period for IMAAVY, a human biological product, which helps the company extend its patent protection. If anyone thinks the dates are wrong, they have until March 30, 2026, to speak up. Also, people can challenge whether the company acted quickly enough during the review by July 27, 2026. This means more time and money could be on the line for the patent holder and competitors.
Next: 2026-01577, Determination of Regulatory Review Period for Purposes of Patent Extension; BIMZELX
The FDA has officially set the review period for BIMZELX, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to keep exclusive rights, which can impact when generic versions hit the market. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until March 30 or July 27, 2026, to speak up.